Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase <scp>II</scp>, Randomized, <scp>Double‐Blind</scp>, <scp>Placebo‐Controlled</scp> Trial
Eric F. Morand(Novartis (Switzerland)), Shalabh Singhal(Bristol-Myers Squibb (United States)), Thomas Wegman(Bristol-Myers Squibb (United States)), Brian J. Sharkey(Bristol-Myers Squibb (United States)), Victoria P. Werth(Philadelphia VA Medical Center), Nikolay Delev(Bristol-Myers Squibb (United States)), Joan T. Merrill(Oklahoma Medical Research Foundation), Coburn Hobar(Bristol-Myers Squibb (United States)), Subhashis Banerjee(Bristol-Myers Squibb (United States)), Vaishali Shah(Bristol-Myers Squibb (United States)), Ian M. Catlett(Bristol-Myers Squibb (United States)), Marilyn C. Pike(Gad Consulting Services (United States)), Ronald van Vollenhoven(Amsterdam University Medical Centers)
Cited by 246
Related Papers
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis
|New England Journal of Medicine|2005|1.1k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)
|Annals of the Rheumatic Diseases|2015|728
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
|Annals of the Rheumatic Diseases|2014|726